271 related articles for article (PubMed ID: 35158897)
41. Management of partial and non-responding cutaneous squamous cell carcinoma.
Jansen P; Lodde GC; Griewank KG; Hadaschik E; Roesch A; Ugurel S; Zimmer L; Livingstone E; Schadendorf D
J Eur Acad Dermatol Venereol; 2022 Jan; 36 Suppl 1():29-34. PubMed ID: 34855242
[TBL] [Abstract][Full Text] [Related]
42. Integrating 40-GEP Testing to Improve Clinical Recommendations for Adjuvant Radiation for Cutaneous Squamous Cell Carcinoma: Multidisciplinary Consensus Guidelines.
Gopal R; Marquardt M; Singh G; Tolkachjov SN; Arron ST
J Clin Aesthet Dermatol; 2024 Mar; 17(3 Suppl 2):S3-S8. PubMed ID: 38495846
[TBL] [Abstract][Full Text] [Related]
43. Checkpoint immunotherapy of cutaneous squamous cell carcinoma in patients suffering from chronic lymphocytic leukaemia: divergent outcomes in two men treated with PD-1 inhibitors.
Jansen P; Lodde GC; Wetter A; Welt A; Stuschke M; Dührsen U; Stoffels I; Klode J; Livingstone E; Zimmer L; Roesch A; Hadaschik E; Griewank KG; Schadendorf D; Ugurel S
J Eur Acad Dermatol Venereol; 2022 Jan; 36 Suppl 1():41-44. PubMed ID: 34855243
[TBL] [Abstract][Full Text] [Related]
44. Guidelines of care for the management of cutaneous squamous cell carcinoma.
; ; Kim JYS; Kozlow JH; Mittal B; Moyer J; Olenecki T; Rodgers P
J Am Acad Dermatol; 2018 Mar; 78(3):560-578. PubMed ID: 29331386
[TBL] [Abstract][Full Text] [Related]
45. Immunotherapy and Systemic Treatment of Cutaneous Squamous Cell Carcinoma.
Aboul-Fettouh N; Morse D; Patel J; Migden MR
Dermatol Pract Concept; 2021 Nov; 11(Suppl 2):e2021169S. PubMed ID: 34877077
[TBL] [Abstract][Full Text] [Related]
46. Cemiplimab for the treatment of advanced cutaneous squamous cell carcinoma.
Hernández-Guerrero T; Doger B; Moreno V
Drugs Today (Barc); 2019 Aug; 55(8):485-494. PubMed ID: 31461085
[TBL] [Abstract][Full Text] [Related]
47. Deciphering the Molecular Landscape of Cutaneous Squamous Cell Carcinoma for Better Diagnosis and Treatment.
Lazar AD; Dinescu S; Costache M
J Clin Med; 2020 Jul; 9(7):. PubMed ID: 32674318
[TBL] [Abstract][Full Text] [Related]
48. Overview of resistance to systemic therapy in patients with breast cancer.
Gonzalez-Angulo AM; Morales-Vasquez F; Hortobagyi GN
Adv Exp Med Biol; 2007; 608():1-22. PubMed ID: 17993229
[TBL] [Abstract][Full Text] [Related]
49. Epidermal growth factor receptor expression is associated with poor outcome in cutaneous squamous cell carcinoma.
Cañueto J; Cardeñoso E; García JL; Santos-Briz Á; Castellanos-Martín A; Fernández-López E; Blanco Gómez A; Pérez-Losada J; Román-Curto C
Br J Dermatol; 2017 May; 176(5):1279-1287. PubMed ID: 27510450
[TBL] [Abstract][Full Text] [Related]
50. Evidence-Based Consensus Recommendations for the Evolving Treatment of Patients with High-Risk and Advanced Cutaneous Squamous Cell Carcinoma.
Rabinowits G; Migden MR; Schlesinger TE; Ferris RL; Freeman M; Guild V; Koyfman S; Pavlick AC; Swanson N; Wolf GT; Dinehart SM
JID Innov; 2021 Dec; 1(4):100045. PubMed ID: 34909742
[TBL] [Abstract][Full Text] [Related]
51. Systemic therapy for advanced cutaneous squamous cell carcinoma.
Fitzgerald K; Tsai KK
Semin Cutan Med Surg; 2019 Mar; 38(1):E67-E74. PubMed ID: 31051028
[TBL] [Abstract][Full Text] [Related]
52. Stage IV cutaneous squamous cell carcinoma: treatment outcomes in a series of 42 patients.
Chapalain M; Baroudjian B; Dupont A; Lhote R; Lambert J; Bagot M; Lebbe C; Basset-Seguin N
J Eur Acad Dermatol Venereol; 2020 Jun; 34(6):1202-1209. PubMed ID: 31587382
[TBL] [Abstract][Full Text] [Related]
53. Risk factors and timing of subsequent cutaneous squamous cell carcinoma in patients with cutaneous squamous cell carcinoma: A retrospective cohort study.
Rodriguez M; Beal BT; Manmohan M; Simmons E; Varra V; Xiong D; Eversman A; Briskin IN; Knackstedt T; Vidimos AT
J Am Acad Dermatol; 2021 Mar; 84(3):719-724. PubMed ID: 32861709
[TBL] [Abstract][Full Text] [Related]
54. Case Report: Dostarlimab for treatment of aggressive cutaneous squamous cell carcinoma.
Gandarillas S; Tang H; Dasgeb B
Front Med (Lausanne); 2024; 11():1322210. PubMed ID: 38529116
[TBL] [Abstract][Full Text] [Related]
55. Analysis of selected risk factors for nodal metastases in head and neck cutaneous squamous cell carcinoma.
Szewczyk M; Pazdrowski J; Golusiński P; Dańczak-Pazdrowska A; Marszałek S; Golusiński W
Eur Arch Otorhinolaryngol; 2015 Oct; 272(10):3007-12. PubMed ID: 25217080
[TBL] [Abstract][Full Text] [Related]
56. Clinical Utility of the 40-Gene Expression Profile (40-GEP) Test for Improved Patient Management Decisions and Disease-Related Outcomes when Combined with Current Clinicopathological Risk Factors for Cutaneous Squamous Cell Carcinoma (cSCC): Case Series.
Au JH; Hooper PB; Fitzgerald AL; Somani AK
Dermatol Ther (Heidelb); 2022 Feb; 12(2):591-597. PubMed ID: 34951694
[TBL] [Abstract][Full Text] [Related]
57. Cemiplimab: A Review in Advanced Cutaneous Squamous Cell Carcinoma.
Lee A; Duggan S; Deeks ED
Drugs; 2020 Jun; 80(8):813-819. PubMed ID: 32306208
[TBL] [Abstract][Full Text] [Related]
58. Surgery for Cutaneous Squamous Cell Carcinoma and its Limits in Advanced Disease.
Moreno-Ramírez D; Silva-Clavería F; Fernández-Orland A; Eiris N; Ruiz de Casas A; Férrandiz L
Dermatol Pract Concept; 2021 Nov; 11(Suppl 2):e2021167S. PubMed ID: 34877075
[TBL] [Abstract][Full Text] [Related]
59. Overcoming Resistance to Immunotherapy in Advanced Cutaneous Squamous Cell Carcinoma.
García-Sancha N; Corchado-Cobos R; Bellido-Hernández L; Román-Curto C; Cardeñoso-Álvarez E; Pérez-Losada J; Orfao A; Cañueto J
Cancers (Basel); 2021 Oct; 13(20):. PubMed ID: 34680282
[TBL] [Abstract][Full Text] [Related]
60. Cutaneous Squamous Cell Carcinoma: From Biology to Therapy.
Corchado-Cobos R; García-Sancha N; González-Sarmiento R; Pérez-Losada J; Cañueto J
Int J Mol Sci; 2020 Apr; 21(8):. PubMed ID: 32331425
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
